Menu

Recent Interviews

Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)

info@cleanlogistics.de

+49-4171-6791300

Interview Clean Logistics: Hydrogen challenge to Daimler + Co.


Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


23. September 2020 | 09:05 CET

BioNTech, CureVac, or Valeo Pharma: who brings the highest return to shareholders?

  • Covid-19
Photo credits: pixabay.com

When the Corona Pandemic started in November 2019 in Wuhan, China, nobody could have guessed the extent of the disease. Socially, economically and politically, Covid-19 has turned the world upside down. With increasing knowledge in dealing with the coronavirus, people around the globe are trying to come to terms with the new state of affairs - as best they can. On the stock market, there are numerous opportunities for investors to participate in further development in the fight against serious diseases.

time to read: 2 minutes by Mario Hose
ISIN: US09075V1026 , NL0015436031 , CA91915B1085


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Tax money accelerates development

The development of medical agents is costly and time-consuming. Politicians and companies are working closely together on research into a vaccine against Covid-19. Social peace is already at stake in many countries, and for this reason, specialized companies must be given financial leeway to get to the goal as quickly as possible: the vaccine. The two German companies BioNTech and CureVac have each received pledges of taxpayers' money in the high three-digit million range with the achievement of milestones.

Strengthening the industry

BioNTech and CureVac offer investors who want to participate in the race for a vaccine with the solid legal and regulatory framework of the European Union and other developed markets. However, it should be noted that the market capitalization is already in the multi-billion range so high expectations have already been priced in. The fight against Covid-19 has brought these companies to the forefront of global competition, which is expected to strengthen the industry for the time after the pandemic, and the experience gained will also be used in other areas of the companies for the development of other products.

Access to patients generates revenue

Anyone afraid of the research and development risk should take a look at Valeo Pharma, as the company focuses on bringing to market products already tried and tested by other biotech companies. The main market for its medical products is Canada. According to its statements, Valeo Pharma can accompany the entire process of handling products. Especially for small researching market participants, specialized companies like Valeo Pharma offer an excellent sales channel. The sales staff are in direct contact with doctors and medical institutions. This is how specific prescription products find their way to the patient.

Marketing authorization enables sales offensive

In the context of the current corona pandemic, Valeo Pharma is working with its partner Ingenew. Ingenew's Hesperco capsules are designed to support the immune system and Valeo Pharma has accompanied the marketing authorization process and is now taking care of the distribution. Pierre Laurin, CEO of Ingenew, explained the importance of the active ingredient in a press release: "(...) Thousands of compounds have been evaluated since the start of the pandemic and the active compound in Hesperco capsules has been repeatedly reported to be one of the best candidate to interfere with the mechanisms SARS-CoV-2 uses to infect our cells. (…)“

Portfolio offers growth potential

Besides Hesperco, Valeo Pharma has eight other products in its portfolio and six more in the pipeline. The latest financing round provides the company with sufficient capital for a sales offensive. The company was able to raise CAD 6.9 million from investors at a share price of CAD 1.20, thus laying the foundation for the future. "(...) The proceeds of this financing will be used to support the launch of several new products in the coming months and to accelerate new growth opportunities," said Steve Saviuk, CEO of Valeo Pharma. With a market capitalization of CAD 75 million, Valeo Pharma costs only a fraction of the market capitalization of BioNTech and CureVac.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

04. February 2021 | 08:15 CET | by Nico Popp

BioNTech, Cardiol Therapeutics, Johnson & Johnson: biotech gems from the well-known to the unknown

  • Covid-19

If there's one industry that's rightfully making big profits these days, it's healthcare companies. The pandemic has kissed the industry awake. In addition to the current relevance around Covid treatment, test procedures, or even vaccinations, there is also a growing awareness that medical innovation depends on research. More and more investors are willing to push promising projects and the general conditions for this could not be better. There is a consensus in politics, society and business that health is the highest good.

Read

21. December 2020 | 07:50 CET | by Stefan Feulner

CureVac, EXMceuticals, Formycom - the undiscovered profiteers of the crisis!

  • Covid-19

The Corona pandemic continues to be the dominant topic of our time. Not a day goes by when new achievements in the fight against the pandemic come to public attention. The battle against Covid-19 is becoming a multi-billion-dollar business. In addition to the well-known profiteers, the vaccine manufacturers BioNTech and Pfizer, Moderna and AstraZeneca and many smaller companies are also profiting. Their potential is still largely unknown on the stock market and is far from being fully exploited.

Read

02. November 2020 | 09:07 CET | by Stefan Feulner

Ballard Power, Saturn Oil & Gas, Amazon - The profiteers of the crisis!

  • Covid-19

The profiteers of the first wave of the Corona pandemic are seen from the most recently published quarterly figures. The well-known FAANG stocks Facebook, Amazon, Apple, Netflix and Alphabet (Google) were able to improve their balance sheets significantly. Besides some winners, the number of losers is much larger. These now either have to fight for survival or are swallowed cheaply by financially more robust competitors. The takeover wave should pick up speed in 2021, across all industries!

Read